bSpillage of cyst contents during surgery is the major cause of recurrences of hydatidosis, also called cystic echinococcosis (CE). Currently, many scolicidal agents are used for inactivation of the cyst contents. However, due to complications in the use of those agents, new and more-effective treatment options are urgently needed. The aim of this study was to investigate the in vitro efficacy of arsenic trioxide (ATO) against Echinococcus granulosus protoscolices. Protoscolices of E. granulosus were incubated in vitro with 2, 4, 6, and 8 mol/liter ATO; viability of protoscolices was assessed daily by microscopic observation of movements and 0.1% eosin staining. A small sample from each culture was processed for scanning and transmission electron microscopy. ATO demonstrated a potent ability to kill protoscolices, suggesting that ATO may represent a new strategy in treating hydatid cyst echinococcosis. However, the in vivo efficacy and possible side effects of ATO need to be explored.
Hydatidosis, also called cystic echinococcosis (CE), is a severe zoonotic disease caused by the tapeworm Echinococcus granulosus at its larval stage. E. granulosus is distributed worldwide (1). Currently, chemotherapy, puncture with aspiration, and surgery are the three main treatments for hydatid cysts (2), with surgery being one of the best choices for treating hydatidosis (3). The possibility of cyst rupture and protoscolex dissemination can result in secondary CE caused by spillage of a large number of protoscolices; spillage of cyst contents during surgical operation is the major cause of recurrences of the disease (4).Instillation of a scolicidal agent into a hepatic hydatid cyst is the most commonly employed measure to prevent their reoccurrence and attendant complications. Many scolicidal agents have been used for inactivation of cyst contents. The agents can destroy parasites (5), but their use can result in some complications, including acute hypernatremia and intracranial bleeding, leading to convulsions and myelinolysis (6). Therefore, there is a clinical need for safe and effective scolicidal solutions.Arsenic trioxide (As 2 O 3 [ATO]) is the main component of arsenolite, an ancient drug used in traditional Chinese medicine for over 5,000 years (7); it was the first effective chemotherapy against cancer, syphilis, parasites, and leukemia and especially in the treatment of patients suffering from acute promyelocytic leukemia (APL) (8). The solution gained popularity as a feed additive for chickens and pigs to prevent parasitic infestations and weight gain (9). In 1905, Harold Thomas of Liverpool used atoxyl, an arsenic derivative, to kill trypanosomes. From 1830 to 1930, it was used to treat African sleeping sickness (10). Moreover, ATO has been shown to be effective, particularly in combination with other drugs, in chronic myeloid leukemia therapy (11,12).Currently, ATO is approved by the FDA for the treatment of acute promyelocytic leukemia (13). Arsenical drugs are still used for treatment of parasitic diseases such ...